Latest news with #ColmConnolly
Reuters
4 days ago
- Business
- Reuters
US appeals court sides with Moderna on COVID patent claims
June 4 (Reuters) - Moderna (MRNA.O), opens new tab convinced a U.S. appeals court on Wednesday to uphold a ruling that undercut patent infringement claims by biotech company Alnylam Pharmaceuticals (ALNY.O), opens new tab over Moderna's blockbuster COVID-19 vaccine Spikevax. The U.S. Court of Appeals for the Federal Circuit upheld, opens new tab a Delaware federal court's decision to interpret Alnylam's two patents in a manner that foreclosed its infringement arguments. Alnylam lost a similar dispute in a related Moderna case last year. It has filed separate, ongoing patent lawsuits over Pfizer's COVID shots. An Alnylam spokesperson said the company is reviewing the Wednesday ruling and considering its options. A Moderna spokesperson said it was pleased with the decision and that its vaccine was "a product of many years of pioneering mRNA platform research and development." Cambridge, Massachusetts-based Alnylam first sued Moderna and Pfizer for patent infringement in 2022 for allegedly using its lipid nanoparticle (LNP) technology in their vaccines to deliver genetic material into the body. The lawsuits are part of a web of patent disputes between biotech companies over COVID shots, which includes a lawsuit filed by Moderna against Pfizer later that year. Moderna and Alnylam jointly agreed to dismiss Alnylam's patent claims in the first case in 2023 after U.S. District Judge Colm Connolly interpreted the patents to cover a type of lipid that Spikevax did not have. A three-judge Federal Circuit panel upheld Connolly's interpretation on Wednesday. The case is Alnylam Pharmaceuticals Inc v. Moderna Inc, U.S. Court of Appeals for the Federal Circuit, No. 23-2357. For Alnylam: Paul Hughes of McDermott Will & Emery For Moderna: Jeffrey Lamken of MoloLamken Read more: Alnylam files patent infringement lawsuits against Pfizer, Moderna Alnylam to appeal ruling on patents related to Moderna's COVID vaccines Moderna fends off Alnylam US patent lawsuit over COVID shots, for now
Reuters
14-05-2025
- Business
- Reuters
Alnylam drops Covid vaccine patent case against Pfizer, BioNTech for now
May 14 (Reuters) - Biotech company Alnylam Pharmaceuticals (ALNY.O), opens new tab conceded defeat for now in a lawsuit against Pfizer (PFE.N), opens new tab and BioNTech ( opens new tab over technology in their COVID-19 vaccine, asking a Delaware federal court on Tuesday to enter a judgment that they did not infringe Alnylam's patents. Alnylam requested that the court, opens new tab end the case after U.S. District Judge Colm Connolly interpreted the company's patents in a way that would not cover Pfizer and BioNTech's vaccine. The company dropped a separate lawsuit over Moderna's COVID-19 shots following a similar ruling favoring Moderna last year. An Alnylam spokesperson said the company was evaluating its options and may appeal. A BioNTech spokesperson said the filing "confirms Pfizer's and BioNTech's position that we do not infringe any valid patents asserted by Alnylam." Cambridge, Massachusetts-based Alnylam sued Pfizer and BioNTech in 2022, alleging their COVID-19 vaccines infringed patents covering the use of its lipid nanoparticles (LNP) to deliver genetic material into the body. Pfizer and BioNTech denied the allegations and argued the patents were invalid. The lawsuit is one of several patent infringement cases filed by biotech companies over technology used in the blockbuster COVID-19 shots, which include an ongoing lawsuit brought by Moderna against Pfizer and BioNTech. The case is Alnylam Pharmaceuticals Inc v. Pfizer Inc, U.S. District Court for the District of Delaware, No. 1:22-cv-00336. For Alnylam: Ethan Townsend, William Gaede, Sarah Columbia, Sarah Fischer and Ian Brooks of McDermott Will & Emery For Pfizer: Arthur Connolly and Alan Silverstein of Connolly Gallagher For BioNTech: Jeremy Tigan and Anthony Raucci of Morris Nichols Arsht & Tunnel Read more: Alnylam files patent infringement lawsuits against Pfizer, Moderna Moderna fends off Alnylam US patent lawsuit over COVID shots, for now
